EN
HI

KOPRAN Share price

KOPRAN

HealthcareSmall

186.02

3.71 (2.03%)
NSE
BSE
Last updated on 19 May, 2025 | 15:30 IST
BUYSELL
Today's High

190.91

Today's Low

180.75

52 Week Low

155.00

52 Week High

369.70

The current prices are delayed, login to your account for live prices

Kopran Chart

KOPRAN Fundamentals

P/E Ratio

32.81

P/B Ratio

2.04

Div. Yield

1.64

Sector P/E

41.77

Sector P/B

4.72

Sec. Div. Yield

0.32

KOPRAN Resistance and Support

Pivot 182.41

Resistance

First Resistance

184.89

Second Resistance

187.48

Third Resistance

189.96

Support

First Support

179.82

Second Support

177.34

Third Support

174.75

KOPRAN Futures & Options

Data Not Found

KOPRAN Shareholding Pattern

    Total Promoters
    Segment
    Percent

    Total Promoters

    43.78%

    Mutual Fund

    0%

    Insurance

    0%

    Foreign Institutional Investors

    0%

    Domestic Institutional Investors

    2.69%

    Retail

    53.53%

    Others

    0%

    Total Promoters
    MAR '18
    43.78%
    JUN '18
    43.78%
    SEP '18
    43.78%
    DEC '18
    43.78%

    KOPRAN Corporate Actions

    DateAgenda
    2025-05-15Audited Results & Final Dividend
    DateEvent TypeAgenda
    2025-05-15Board MeetingAudited Results & Final Dividend

    KOPRAN News

    Morning market chatter: Ruchi Soya, Jet Airways, Kopran & Reliance Power hit upper circuit; read to know more!

    Jun 29 2021 11:20:51
    Read More

    About KOPRAN AboutThe

    NSE : 1919  
    BSE : 524280  
    ISIN : INE082A01010  

    HISTORY BACKGROUND & PRESENT ACTIVITIES OF THE COMPANYKopran Ltd. was incorporated on April 26 1958 as a private limitedCompany under the name Kopran Chemical Company Pvt. Ltd. promoted byRamanlal V Shah Sevantilal A Shah Chimanlal G Sheth and Jivanlal MShah. The Company's name was changed to Kopran Chemical Company Limitedon August 24 1984 and further changed to Kopran Limited on August 221990.The Parijat Group acquired the Company in 1980 and revived it. TheCompany has since been making profits and the accumulated losses werewiped off by 1980-81. In August 1984 the Company was converted into apublic limited company and the name of the company was changed toKopran Ltd..Originally Kopran Ltd. manufactured pharmaceutical formulationsprominent amongst which are VENT TINI LOKIT and CISAPID. Theproduction of bulk drugs intermediaries was introduced in 1983. TheCompany established additional facilities in 1993 for the manufactureof 7- ADCA Cefadroxil C.I.M.C. Pen-G Acylase Enzyme and expandedfacilities for manufacture of SSP's. A Public Issue aggregating to Rs.14.40 Crs funded the Project. There were minor delays in theimplementation.Since then Kopran Ltd. has built up its strengths in the production ofwide range of Semi Synthetic Penicillin (SSPs) such as AmpicillinTrihydrate Amoxycillin Trihydrate and Cloxacillin Sodium. In 1986Rifampicin was launched in technical co-operation with YuhanCorporation South Korea. To support the expanding product base theCompany integrated backwards into manufacture of 6-APA an intermediaterequired for production of SSPs.The Company subsequently de-merged its SSP & 6-APA Bulk Drugs divisioninto a separate company namely KDL Biotech Ltd. (KDL) formerly knownas Kopran Drugs Ltd.. This demerger is primarily to enable the Companyto focus on its formulation business and specialty bulk drugs businesswhile KDL would become a dedicated SSP bulk drugs manufacturer.The formulation division has since then expanded and was structuredinto various strategic business units to enable exploitation of thedomestic and the international formulations market with a larger rangeof formulations. KL's main focus is on cardiology respiratorygastro-enterology anti-infectives and pain management. As a part ofits growth strategy KL plans to develop new products in therapeuticgroups like diabetics central nervous system and life style products.The company can undertake the activities proposed by it in view of thepresent approvals and no further approvals from any GovernmentAuthorities /RBI are required by the company to undertake the proposedactivities.As of March 31 2001 the Company's product portfolio consists of:Cardiovasculars 58%Respiratory 16%Alimentary 15%Anti-Infective 9%Musculo-Skeletals 2%The specialty bulk drug unit situated at Mahad provides most of the rawmaterials required for formulations manufactured for the domestic andthe export market.The Company has received certification under World Health Organization- Good Manufacturing Practice. The certificate WHO.GMP-Cer/409-2001/886/11 is valid up to 30th June 2002.

    KOPRAN Management

    NamePosition
    Mr. Susheel G Somani Chairman
    Mr. Surendra Somani Executive Vice Chairman
    Mr. Adarsh Somani Director
    Mr. Varun Somani Director
    Dr. Siddhan Subramanian Independent Director
    Read More

    KOPRAN FAQs

    KOPRAN शेयर का खरीद मूल्य 186.02 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

    KOPRAN शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

    KOPRAN शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 32.81 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

    KOPRAN शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.04 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

    KOPRAN शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 4.72 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

    KOPRAN का मार्केट कैप 898.25 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

    KOPRAN शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 369.70 और 155.00 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

    KOPRAN Share Key Metrics

    Volume
    2.69 L
    Market Cap
    898.25 CR
    LTQ@LTP
    412@186.02
    ATP
    185.74
    Var Margin
    25.73 %
    Circuit Range
    145.84-218.77
    Delivery %
    55.74 %
    Value
    5.00 CR
    ASM/GSM
    No
    Market Lot
    1